Type 2 diabetes Flashcards
Is type 1 or type 2 diabetes more assoc. with a family history?
Type 2:
- 40% lifetime risk in offspring if parent diagnosed
- if both parents it’s a near to 100% risk
Describe the pathophysiology of T2DM
Obese/sedentery = fat releases fatty acids/adipokines = insulin resistance
- usually this insulin resistance is responded to by pancreatic B cells which release more insulin
- in T2DM B cells have genetic abnormality which prevents them from responding
-progressive disease, as the disease progresses more an more B cells deteriorate
What is ‘insulin resistance syndrome’?
90% T2DM are insulin resistant which is also assoc with:
- HTN
- Hyperlipidaemia
- hyperglycaemia
- PCOS
What is the metabolic syndrome?
Insulin resistance/T2DM + 2 others:
- microalbuminaemia
- obesity
- hypertension
- dyslipidaemia
=3X risk of stroke/MI/CHD/CVD
How does T2DM present?
Symptoms:
-blurred vision (sugary fluid in eye shrivels lens), recurrant UTI, tiredness, polyuria
Screening:
-overweight/obese/FH of T2DM
Concurrent illness:
-glucose measured in work up for CHD
What are the treatment principles of T2DM?
Treat symptoms: lower BG levels
Prevent microvascular complications: aim for HbA1c < 7%
Prevent cardiovascular complications: cholesterol, BP control, antiplatelets
Screen for complications whilst treatable: eye/neuropathy/renal
What is the first step in the management of T2DM?
Lifestyle
Weight loss aim 5-10kg a year
Healthy eating:
- reduce refined carbs
- reduce fat intake
- increasing fruit and veg
- reducing salt
- alcohol
Describe the pharmacological management of T2DM according to SIGN guidance
Glycaemic target <48mmol/mol or individualised for monotherapy
For dual therapy target <53mmol/mol
For triple therapy <58mmol/mol
1st line: metformin (or sulphonylurea if intolerant)
2nd line: ADD one of
- sulphonylurea
- Thiazolidinedione (pioglitazone only one) if hypo/bone fracture worry and no CHD
- DPP IV inhibitor if hypos/weight gain a concern
3rd line: ADD or SUBSTITUTE one with:
- Thiazolidinedione
- DPP IV inhibitor
- insulin injection before bed
- GLP 1 agonist injection if desire to lose weight and BMI>30 and usually <10yr from diagnosis
Treatment with SGLT-2 inhibitors monotherapy may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated and:
- a DPP-4 inhibitor would otherwise be prescribed and
- a sulfonylurea or pioglitazone is not appropriate.
Metformin
- what type of drug is this?
- how does it work?
- Desirable effects
- adverse effects
Biguanide drug
Mechanism: reduces hepatic glucneogenesis, increases glucose uptake and utilisation by skeletal muscle, reduces carb. absorption and increases fatty acid oxidation (insulin sensitiser)
Desirable effects: oral, no hypos, wt loss, prevents macro/micro complications, safe in preg. (gestational DM), used in PCOS/NAFLD, lowers lipids
Adverse effects: GI upset, accumalation in kidneys, liver failure, rash, interferes with vit B12 and folic acid, lactic acidosis rarely
Prescribing notes:
- Avoid or stop if eGFR <30ml/min or serum creatinine >150μmol/l
- Half dose if eGFR 30-45 ml/min
- Temporarily withhold if IV contrast being used eg. Angiography, CT scan (renal)
- Discontinue if advanced cirrhosis/liver failure
- Discontinue if risk of lactic acidosis eg encephalopathy, alcohol excess
- May be beneficial in Non-alcoholic fatty liver disease (NAFLD)
Gliclazide:
- what type of drug is this?
- how does it work?
- Desirable effects
- adverse effects
Sulphonylurea
Mechanism: insulin secretagogue (secretes insulin)
Desirable effects: reduces HbA1c more rapidly than insulin sensitisers
Adverse effects:
- hypoglycaemia
- wt gain
- GI upset
- headache
- blood dyscrasia
- liver dysfunction
avoid in renal or hepatic failure
Pioglitazone
- what type of drug is this?
- how does it work?
- adverse effects
Thiazolidinedione
Mechanism: PPar gamma agonist, reduces the amount of insulin needed to maintain blood glucose levels as it adapts insulin signalling
Adverse effects:
- wt gain
- heart failure due to fluid retention
- bone fractures
Gliptins e.g. vildagliptin
- what type of drug is this?
- how does it work?
- Desirable effects
- adverse effects
DPP-IV inhibitor (DPP-IV inactivates GLP-1 and GIP which are hormones that stimulate insulin release)
Mechanism: enhance insulin release and decrease glucagon release
Desirable effects: no hypos, weight neutral
Adverse: not that potent
Exenatide
- what type of drug is this?
- how does it work?
- Desirable effects
- adverse effects
GLP-1 agonist
Mechanism: mimic action of GLP-1 (hormone that stimulates insulin release) but are longer lasting
Desirable:
- little hypo risk
- early satiety
- reduces appetite
- decrease hepatic fat accumalation
Adverse:
- nausea
- injections
Dapaglifozin
- what type of drug is this?
- how does it work?
- Desirable effects
- adverse effects
SGLT2 inhibitor
Mechanism: blocks reabsorption of glucose at the SGLT2 transporter in the proximal tubule = glucose voided with water
Desirable: weight loss and no or little chance of hypo
Adverse effects: sugar in urine = thrush/UTI
Blood pressure in diabetes: what are the targets? what therapy is used?
Target systolic: <130mmHg
Target diastolic: 80mmHg or less
-ACE-Inhibitor
If Afro-carribean give ACEI + thiazide diuretic/calcium channel blocker
DONT GIVE B BLOCKER ANY DIABETES INCREASE INSULIN RESISTANCE